Dopamine receptor polymorphisms and drug response in schizophrenia

Pharmacogenomics

Volumn 2, Issue 3, 2001, Pages 251-261

  Scharfetter, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Association; Dopamine; Pharmacogenetic; Response; Schizophrenia

Indexed keywords

ARGININE; CLOZAPINE; CYCLIC AMP; CYSTEINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; EMONAPRIDE; GLYCINE; HALOPERIDOL; LEUCINE; NEUROLEPTIC AGENT; PHENYLALANINE; PROLINE; RISPERIDONE; SERINE; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; PHARMACOGENETICS; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; VARIABLE NUMBER OF TANDEM REPEAT;

HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA;

EID: 0034845559     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.2.3.251     Document Type: Review

References (51)

1. Linkage and associated studies in schizophrenia
2. Recent progress in psychiatric genetics - Some hope but no hype
3. Future directions of research in statistical genetics
4. Twin studies of schizophrenia: From bow-and-arrow concordances to star wars MX and functional genomics
5. Schizophrenia epigenesis
6. Epidemiology of schizophrenia: An European perspective
7. Important issues in the drug treatment of schizophrenia
8. Dopamine in schizophrenia: A review and reconceptualization
9. 2 receptor explain the action of atypical antipsychotics? A new hypothesis
10. Polymorphisms in dopamine receptors: What do they tell us?
11. Dopamine receptors: Novel insights from biochemical and genetic studies
12. Pharmacogenomics and schizophrenia
13. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
14. 311 polymorphism in schizophrenia
15. 4) receptors in schizophrenia
16. 2 receptor polymorphism at the TaqI A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients
17. 2 receptor gene
18. Pharmacogenomics and schizophrenia
19. 3 receptor with the semliki forrest virus system
20. 3 dopamine receptor MscI polymorphism with schizophrenia: Analysis of symptoms ratings, family history, age at onset and movement disorders
21. 9 Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response
22. 3 receptor gene and schizophrenia
23. 3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients
24. 3 receptor gene variants and substance abuse in schizophrenia
25. 3 receptor gene and schizophrenia
26. 3 and schizophrenia
27. 3 receptor gene polymorphisms: Probable effects of family history of schizophrenia?
28. 3 receptor gene locus in two independent samples
29. 3 receptor gene
30. 3 dopamine receptor gene
31. 3 receptor gene and schizophrenia
32. 3 receptor gene in schizophrenic patients
33. DRD3 and DAT1 genes in schizophrenia: An association study
34. 4 receptor gene polymorphisms and neuroleptic response in schizophrenia
35. 4 receptor gene
36. 4 receptor subtypes and response to clozapine
37. 4 receptor gene (DRD4) in schizophrenic patients
38. Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors
39. 4 dopamine receptor (DRD4) gene does not predict response to clozapine
40. 4 receptor gene
41. 4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects
42. Dopamine receptor 48-bp repeat polymorphism: No association with response to antipsychotic treatment, but association with catatonic schizophrenia
43. 4 receptor and response to antipsychotic drugs
44. 2 receptor gene and tardive dyskinesia in schizophrenia
45. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
46. Application of pharmacogenetics to psychotic disorders: The first consensus conference
47. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
48. The use of single nucleotide polymorphisms in the isolation of common disease genes
49. Extreme discordant phenotype methodology: An intuitive approach to clinical pharmacogenetics
50. Pharmacogenetic prediction of clozapine response
51. Pharmacogenetics in schizophrenia